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Combination therapies are becoming a focal point in cancer immunotherapy. In this issue of Cancer Cell,
Johnston and colleagues identify the TIGIT/CD226 pathway, which provides significant interest for combina-
tion with PD-1 pathway blockade to improve anticancer CD8+ T cell responses, because it acts by a novel
mechanism to regulate CD8+ T cell functions within the tumor microenvironment.Recent advances in immunotherapy high-
light the immune system’s ability to res-
pond to many types of cancers. Unfortu-
nately, endogenous antitumor immunity
is typically inadequate to eradicate tu-
mors.Adominantmechanismcontributing
to poor antitumor immunity is expression
of inhibitory receptors including PD-1,
CTLA-4, TIM-3, and LAG-3, which limit
tumor-infiltrating CD8+ T cell functions.
While blockade of PD-1 and/or CTLA-4
have shown significant clinical promise,
most patients have not responded opti-
mally, highlighting the need for additional
approaches (Callahan and Wolchok,
2013). In this issue of Cancer Cell,
Johnston et al. (2014) identify the T cell
coinhibitory receptorTIGIT (Tcell immuno-
globulin and immunoreceptor tyrosine-
based inhibitory motif [ITIM] domain) as
an attractive candidate for coblockade
with PD-1 pathway inhibitors to reverse
CD8+ T cell dysfunction in cancer and
chronic infection.
TIGIT was identified by a genomic
search for structures shared by other
immunomodulatory receptors, including
a conserved ITIM (Yu et al., 2009). TIGIT
is expressed by subsets of regulatory
and memory CD4+ T cells, CD8+ T cells,
and natural killer (NK) cells. TIGIT modu-
lates NK cell killing and CD4+ T cell activa-
tion and promotes tolerance by increasing
interleukin 10 (IL-10) while suppressing
IL-12 production by dendritic cells (Sta-
nietsky et al., 2013; Yu et al., 2009). The
ligand for TIGIT is poliovirus receptor
(PVR), which is shared with CD226, a
costimulatory molecule important in anti-
viral and antitumoral responses (Gilfillanet al., 2008; Welch et al., 2012). Thus,
TIGIT is an important immunomodulator,
but its role in CD8+ T cell responses and
the molecular and functional relationships
between TIGIT and CD226 have been
unclear.
Johnston et al. (2014) identified a crit-
ical role for TIGIT in regulating exhausted
CD8+ T cell responses in tumors and
chronic infection. TIGIT was associated
with multiple human tumor types and
was highly expressed on tumor-infiltrating
lymphocytes (TILs) in CT26 and EMT6
tumor models. Despite high expression
of PD-1 and TIGIT by a large fraction of
TILs, single blockade of TIGIT or PD-L1,
the main ligand for PD-1, had little effect
on tumor volume or survival. Strikingly,
however, coblockade of TIGIT and PD-
L1 led to complete responses in the ma-
jority of mice and substantially improved
survival. Mechanistically, coblockade im-
proved intratumoral interferon g (IFNg)
production, with no difference in the
tumor-draining lymph node (LN).
Johnston et al. (2014) also examined
CD8+ T cell responses during chronic lym-
phocytic choriomeningitis virus (LCMV)
infection in mice. Here, TIGIT was impor-
tant for modulating antiviral CD8+ T cell
priming but played a less critical role
in established exhausted CD8+ T cells.
Importantly, combining TIGIT and PD-L1
blockade resulted in superior reversal of
exhaustion and viral control than PD-L1
blockade alone (Johnston et al., 2014). It
is unclear why TIGIT blockade alone can
promote cytokine production in tumors
but not chronic infection, though differ-
ences in antiviral versus antitumor CD8+Cancer Cell 26,T cell responses are likely to exist,
including the severity of dysfunction,
availability of ligands, degree of inflamma-
tion, and nature of systemic (e.g., LCMV)
versus organ-specific (e.g., solid tumor)
immune responses. More work is needed
to understand the cellular and molecular
mechanisms underlying this synergy.
Inhibitory receptors may regulate T cell
functions by different mechanisms, in-
cluding (1) cell-intrinsic modulation via
the receptor’s intracellular signaling do-
main(s), (2) indirect effects by competing
with costimulatory receptors for shared
ligands on APCs, and (3) modulating
functions of the cells expressing ligand
(Figure 1). Intriguingly, Johnston et al.
(2014) found TIGIT’s immunomodulatory
effects depend on CD226. TIGIT/CD226
competition for ligand could partially
explain this dependence (Figure 1) (Yu
et al., 2009). However, here, TIGIT is
shown to directly interact with CD226,
where TIGIT prevents CD226 homodime-
rization (Johnston et al., 2014) (Figure 1).
TIGIT’s ability to interfere with CD226
signaling by physically preventing homo-
dimerization rather than simply com-
peting for ligand represents a novel
mechanism by which inhibitory receptors
can exert their immunomodulatory ef-
fects. This dynamic interplay is reminis-
cent of NK cell regulation, where signals
from various activating and inhibitory
receptors are summed, with the net
determining whether the NK cells will
execute their effector functions (Sun
and Lanier, 2011). Importantly, blocking
CD226 completely abrogated the effect
of TIGIT/PD-L1 coblockade in the tumorDecember 8, 2014 ª2014 Elsevier Inc. 785
Figure 1. Putative Molecular Mechanisms Involved in Synergy Observed during Coblockade
(1) Inhibitory receptors can deliver signals directly to the T cell by recruiting proteins to the intracellular
domains (e.g., the ITSM of PD-1 recruiting SHP2). (2) Costimulatory and coinhibitory receptors that share
ligands can compete for ligand binding (e.g., TIGIT and CD226 competing for PVR). (3) Inhibitory receptor
binding can deliver an inhibitory signal to the ligand-expressing cells (e.g., TIGIT binding PVR induces
functional changes in dendritic cells.) (4) Novel mechanism of inhibitory receptor function identified by
Johnston et al. (2014) where inhibitory receptors can directly block homodimerization of costimulatory re-
ceptors, mediating the inhibitory effect by preventing the costimulatory signal from acting (e.g., TIGIT
physically preventing CD226 from signaling). Red lines indicate inhibitory signals, green lines indicate
stimulatory signals.
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T cell frequency in the tumor-draining LN
compared to coblockade alone (Johnston
et al., 2014). These data suggest unique
interplays among CD226, TIGIT, and PD-
1 in the tumor microenvironment.
While the precise mechanisms of T cell
co-inhibition by PD-1 and TIGIT interac-
tions remain to be fully defined, at a
cellular level, (1) PD-1 and TIGIT could
both modulate T cell functions in a cell-
intrinsic manner; (2) PD-1 could signal
into the T cell, while TIGIT-PVR inter-
actions modulate PVR-expressing cell
function; or (3) signals delivered into
the ligand-expressing cell for both PD-1
and TIGIT could account for synergy in
coblockade. At the molecular level, it
will be important to determine if TIGIT’s
ITIM contributes to its mechanism of
action (Figure 1) and if this domain is786 Cancer Cell 26, December 8, 2014 ª201needed for CD226 signal disruption.
Additionally, it will be important to deter-
mine if sharing the same signaling do-
mains has functional ramifications when
multiple inhibitory receptors are acting
simultaneously on the same cell (e.g.,
PD-1 and TIGIT both contain an ITIM).
However, PD-1’s immunoreceptor tyro-
sine-based switch motif (ITSM) is
thought to be the main signaling motif
in T cells (Parry et al., 2005). In deciding
which combination of receptors to
block in patients, it will be important to
determine whether blocking multiple re-
ceptors with the same signaling motifs
has added benefit or if synergistic effects
come from blocking receptors with
distinct signaling motifs and/or modes
of action.
A key question underlying the mech-
anism of inhibitory receptor blockade4 Elsevier Inc.for cancer immunotherapy is whether
blockade acts on tumor-specific T cells
within tumors, the secondary lymphoid
organs, or both. Understanding this issue
is essential to developing predictive bio-
markers of immunotherapy and to deter-
mine the anatomical location best to
performbiomarker assessment. This infor-
mation will also be critical to determine the
mechanisms involved in enhancing anti-
tumor immunity. Johnston et al. (2014)
show that coblockade of PD-L1 and TIGIT
boosted cytokine production by CD8+
T cells within the tumor microenvironment
rather than in the tumor-draining LN. How-
ever, it is unclear whether the enhance-
ment is restricted to TILs present in the
tumor at the time of blockade or if immu-
notherapy drives CD8+ T cells from sec-
ondary lymphoid organs into tumors.
Tumor-specific CD8+ T cells in the sec-
ondary lymphoid organs are likely less
dysfunctional and retain higher prolifera-
tive potential than those within the tu-
mor microenvironment, providing a po-
tential reservoir that could contribute
to responses following immunotherapy.
Furthermore, previous work has shown
that CD8+ T cells expressing the highest
PD-1 levels preferentially reside in nonlym-
phoid tissues and are resistant to reversal
of exhaustion by PD-1 pathway blockade
alone, suggesting the need for a reservoir
of less dysfunctional cells in lymphoid or-
gans (Blackburn et al., 2008; Paley et al.,
2012). A better understanding of these
population dynamics in tumor settings will
be critical for designing and implementing
optimal immunotherapy regiments.
With combination therapy becoming
central to immunotherapeutic approaches
for cancer, selecting the right combination
will be critical. Understanding how and
when to block molecules such as TIGIT
and PD-1 together, separately, or in com-
bination with other targets will depend on
deeper knowledge of expression patterns
and underlying molecular mechanisms.
Johnston et al.’s study on TIGIT highlights
this pathway as one of substantial interest
for further investigation.REFERENCES
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